DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
4.205
+0.185 (4.60%)
Nov 21, 2024, 1:55 PM EST - Market open
DiaMedica Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
179.83M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 444.20M |
Heron Therapeutics | 137.74M |
Biodesix | 65.56M |
2seventy bio | 45.62M |
BrainsWay | 38.63M |
Cellectis | 36.04M |
Senseonics Holdings | 22.21M |
Caribou Biosciences | 11.48M |
DMAC News
- 7 days ago - DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 days ago - DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results - Business Wire
- 7 days ago - DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 9 days ago - DiaMedica Therapeutics to Participate in Upcoming Craig-Hallum 15th Annual Alpha Select Conference - Business Wire
- 15 days ago - DiaMedica Therapeutics to Provide a Business Update and Report Third Quarter 2024 Financial Results November 14, 2024 - Business Wire
- 6 weeks ago - DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
- 2 months ago - DiaMedica Therapeutics Upcoming Conference Participation - Business Wire
- 3 months ago - DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results - Business Wire